9 citations
,
December 2014 in “British Journal of Dermatology” This letter discusses potential hair loss effects of Hedgehog inhibitors but presents no new clinical findings, urging further exploration of this possible class effect.
May 2024 in “Deleted Journal” This study reports that chemotherapy-induced hair loss affects up to 65% of patients, typically within 1 to 3 weeks of treatment, while scalp cooling may help prevent severe hair loss with taxane-based therapies.
127 citations
,
August 2016 in “The oncologist” This paper reviews adverse events related to hedgehog pathway inhibitors in advanced basal cell carcinoma patients, reporting no new clinical results but aiming to inform healthcare professionals for improved patient care.
25 citations
,
January 2021 in “Journal of drugs in dermatology” This review reports that sonidegib and vismodegib, two Hedgehog inhibitors used for treating advanced basal cell carcinoma, have similar efficacy and safety profiles, but differ in pharmacokinetics, with sonidegib achieving peak concentration more rapidly and reaching steady state later than vismodegib.
21 citations
,
November 2021 in “Cells” This review discusses the challenges and opportunities in targeting the hedgehog pathway for aggressive cancers, emphasizing the complexities of treatment resistance, immune response, and the potential of combining immune checkpoint inhibitors with hedgehog pathway inhibitors, but reports no new clinical results.